Saturday, June 6, 2026

Search
HomeBusiness NewsSalubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody...
Business News

Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Con…

0
3
- Advertisement -

GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced updated data from the Phase 1/2 study of JK06, a 5T4-targeted antibody drug…


Click here to view the original article.

- Advertisment -
Previous article
New drug functionally cures hepatitis B. The European Association for the Study of the Liver Congress in Milan, has reported that a drug called bepirovirsen achieved a functional cure in 19% of patients in two large phase 3 clinical trials, with rates rising to 26% in patients with lower baseline
Next article
Federal government blow for Victoria Park Brisbane 2032 Games stadium opponents as urgent appeals rejected

RELATED ARTICLES

- Advertisement -

Recently Viewed

Load more

FEATURED

POPULAR POSTS

POPULAR CATEGORY

The Australian Online News Network acknowledges the traditional custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

FOLLOW US

© 2024 Australian Online News | Privacy Policy